Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

The validity of progression‐free survival 2 as a surrogate trial end point for overall survival

(2022) Rachel G. Woodford et al.   CANCER

653O Pembrolizumab (pembro) vs placebo as adjuvant therapy for patients (pts) with renal cell carcinoma (RCC): Patient-reported outcomes (PRO) in KEYNOTE-564

(2021) T.K. Choueiri et al.   ANNALS OF ONCOLOGY

Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma

(2021) Toni K. Choueiri et al.   NEW ENGLAND JOURNAL OF MEDICINE

Adjuvant Sorafenib for Renal Cell Carcinoma at Intermediate or High Risk of Relapse: Results From the SORCE Randomized Phase III Intergroup Trial

(2020) Tim Eisen et al.   JOURNAL OF CLINICAL ONCOLOGY

Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

(2019) Bernard Escudier et al.   ANNALS OF ONCOLOGY

Adjuvant Vascular Endothelial Growth Factor–targeted Therapy in Renal Cell Carcinoma: A Systematic Review and Pooled Analysis

(2018) Maxine Sun et al.   EUROPEAN UROLOGY

Axitinib versus placebo as an adjuvant treatment of renal cell carcinoma: results from the phase III, randomized ATLAS trial

(2018) M Gross-Goupil et al.   ANNALS OF ONCOLOGY

Randomized Phase III Trial of Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma

(2017) Robert J. Motzer et al.   JOURNAL OF CLINICAL ONCOLOGY

Systemic Therapy for Metastatic Renal-Cell Carcinoma

(2017) Toni K. Choueiri et al.   NEW ENGLAND JOURNAL OF MEDICINE

Recurrence in Localized Renal Cell Carcinoma: a Systematic Review of Contemporary Data

(2017) Jacqueline M. Speed et al.   Current Urology Reports

Adjuvant Treatment for High-Risk Clear Cell Renal Cancer

(2017) Naomi B. Haas et al.   JAMA Oncology

Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial

(2016) Naomi B Haas et al.   LANCET

Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma after Nephrectomy

(2016) Alain Ravaud et al.   NEW ENGLAND JOURNAL OF MEDICINE

Multiple Testing in Group Sequential Trials Using Graphical Approaches

(2013) Willi Maurer et al.   Statistics in Biopharmaceutical Research